507 related articles for article (PubMed ID: 26181108)
21. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
[TBL] [Abstract][Full Text] [Related]
22. Significance of low level infliximab in the absence of anti-infliximab antibodies.
Ungar B; Anafy A; Yanai H; Ron Y; Yavzori M; Picard O; Fudim E; Loebstein R; Kopylov U; Chowers Y; Dotan I; Eliakim R; Ben-Horin S
World J Gastroenterol; 2015 Feb; 21(6):1907-14. PubMed ID: 25684959
[TBL] [Abstract][Full Text] [Related]
23. A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease.
Piester T; Frymoyer A; Christofferson M; Yu H; Bass D; Park KT
Inflamm Bowel Dis; 2018 Jan; 24(2):227-234. PubMed ID: 29361094
[TBL] [Abstract][Full Text] [Related]
24. Clinical efficacy of infliximab level and anti-infliximab antibody measurement in patients with inflammatory bowel disease: An audit.
Dave MB; Dherai AJ; Desai DC; Keny BG; Shetty DN; Kulkarni S; Peddy K; Ashavaid TF
Indian J Gastroenterol; 2020 Oct; 39(5):426-434. PubMed ID: 33118097
[TBL] [Abstract][Full Text] [Related]
25. Long-term clinical outcome after infliximab discontinuation in patients with inflammatory bowel disease.
Lee JM; Kim YJ; Lee KM; Yoon H; Lee BI; Kim DB; Kang D
Scand J Gastroenterol; 2018; 53(10-11):1280-1285. PubMed ID: 30351977
[TBL] [Abstract][Full Text] [Related]
26. Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease.
Pallagi-Kunstár É; Farkas K; Szepes Z; Nagy F; Szűcs M; Kui R; Gyulai R; Bálint A; Wittmann T; Molnár T
World J Gastroenterol; 2014 May; 20(17):5031-5. PubMed ID: 24833846
[TBL] [Abstract][Full Text] [Related]
27. Forecasted infliximab concentrations during induction predict time to remission and sustained disease control of inflammatory bowel disease.
Vermeire S; Dubinsky MC; Rabizadeh S; Panetta JC; Spencer EA; Dreesen E; D'Haens G; Dervieux T; Laharie D
Clin Res Hepatol Gastroenterol; 2024 Jun; 48(6):102374. PubMed ID: 38750934
[TBL] [Abstract][Full Text] [Related]
28. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
[TBL] [Abstract][Full Text] [Related]
29. Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group).
Close P; Bichler J; Kerry R; Ekman S; Bueller HR; Kienast J; Marbet GA; Schramm W; Verstraete M
Coron Artery Dis; 1994 Nov; 5(11):943-9. PubMed ID: 7719527
[TBL] [Abstract][Full Text] [Related]
30. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis.
Nanda KS; Cheifetz AS; Moss AC
Am J Gastroenterol; 2013 Jan; 108(1):40-7; quiz 48. PubMed ID: 23147525
[TBL] [Abstract][Full Text] [Related]
31. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions.
Duburque C; Lelong J; Iacob R; Seddik M; Desreumaux P; Fournier C; Wallaert B; Cortot A; Colombel JF
Aliment Pharmacol Ther; 2006 Sep; 24(5):851-8. PubMed ID: 16918890
[TBL] [Abstract][Full Text] [Related]
32. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease.
Steenholdt C; Al-khalaf M; Brynskov J; Bendtzen K; Thomsen OØ; Ainsworth MA
Inflamm Bowel Dis; 2012 Dec; 18(12):2209-17. PubMed ID: 22344964
[TBL] [Abstract][Full Text] [Related]
33. Anti-infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease.
Zitomersky N; Chi L; Liu E; Bray KR; Papamichael K; Cheifetz AS; Snapper SB; Bousvaros A; Silvester JA
J Pediatr Gastroenterol Nutr; 2024 Feb; 78(2):261-271. PubMed ID: 38374555
[TBL] [Abstract][Full Text] [Related]
34. Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease.
Merras-Salmio L; Kolho KL
J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):272-278. PubMed ID: 27149256
[TBL] [Abstract][Full Text] [Related]
35. Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD.
van Schaik T; Maljaars JP; Roopram RK; Verwey MH; Ipenburg N; Hardwick JC; Veenendaal RA; van der Meulen-de Jong AE
Inflamm Bowel Dis; 2014 Dec; 20(12):2292-8. PubMed ID: 25230167
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
Warman A; Straathof JW; Derijks LJ
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
[TBL] [Abstract][Full Text] [Related]
37. Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar.
Buurman DJ; Blokzijl T; Festen EAM; Pham BT; Faber KN; Brouwer E; Dijkstra G
PLoS One; 2018; 13(12):e0208922. PubMed ID: 30533022
[TBL] [Abstract][Full Text] [Related]
38. Factors associated with reduced infliximab exposure in the treatment of pediatric autoimmune disorders: a cross-sectional prospective convenience sampling study.
Funk RS; Shakhnovich V; Cho YK; Polireddy K; Jausurawong T; Gress K; Becker ML
Pediatr Rheumatol Online J; 2021 May; 19(1):62. PubMed ID: 33933127
[TBL] [Abstract][Full Text] [Related]
39. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
[TBL] [Abstract][Full Text] [Related]
40. Biosimilar infliximab in paediatric inflammatory bowel disease: Efficacy, immunogenicity and safety.
Dipasquale V; Romano C
J Clin Pharm Ther; 2020 Dec; 45(6):1228-1234. PubMed ID: 32743840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]